These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38723233)

  • 1. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
    Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
    JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
    Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
    Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
    Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
    Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
    Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
    Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
    Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
    Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
    Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
    Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
    Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
    Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
    Park S; Ock CY; Kim H; Pereira S; Park S; Ma M; Choi S; Kim S; Shin S; Aum BJ; Paeng K; Yoo D; Cha H; Park S; Suh KJ; Jung HA; Kim SH; Kim YJ; Sun JM; Chung JH; Ahn JS; Ahn MJ; Lee JS; Park K; Song SY; Bang YJ; Choi YL; Mok TS; Lee SH
    J Clin Oncol; 2022 Jun; 40(17):1916-1928. PubMed ID: 35271299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
    Takei S; Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Front Immunol; 2024; 15():1348034. PubMed ID: 38464519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
    Wasilewski D; Onken J; Höricke P; Bukatz J; Murad S; Früh A; Shaked Z; Misch M; Kühl A; Klein O; Ehret F; Kaul D; Radbruch H; Capper D; Vajkoczy P; Horst D; Frost N; Bischoff P
    J Neurooncol; 2024 Mar; 167(1):155-167. PubMed ID: 38358406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
    De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
    J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
    Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
    Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
    Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
    Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
    van Eekelen L; Spronck J; Looijen-Salamon M; Vos S; Munari E; Girolami I; Eccher A; Acs B; Boyaci C; de Souza GS; Demirel-Andishmand M; Meesters LD; Zegers D; van der Woude L; Theelen W; van den Heuvel M; Grünberg K; van Ginneken B; van der Laak J; Ciompi F
    Sci Rep; 2024 Mar; 14(1):7136. PubMed ID: 38531958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.